The competitive /V-methyl-Daspartate antagonist MDL-100,453 was used to determine whether a neuroprotective effect is demonstrable when the drug is administered beginning 30 minutes after the initiation of focal ischemia and whether the effect is related to blood levels of the drug.
Background and Purpose The competitive /V-methyl-Daspartate antagonist MDL-100,453 was used to determine whether a neuroprotective effect is demonstrable when the drug is administered beginning 30 minutes after the initiation of focal ischemia and whether the effect is related to blood levels of the drug.
Methods Forty-eight Sprague-Dawley rats were randomly assigned to one of four intravenous treatment categories: a bolus of 100 mg/kg MDL-100,453 followed by a saline infusion for 24 hours, isotonic saline as a bolus and 100 mg/kg per 24 hours of MDL-100,453 as an infusion over 24 hours, active drug in the bolus and 24-hour infusion, and control treatment of an isotonic saline bolus and infusion. Focal cerebral ischemia was induced by the intraluminal suture, middle cerebral artery occlusion method. The drug infusion was accomplished by an osmotic minipump implanted under the skin and attached to the jugular vein, which delivered drug or vehicle over a period of 24 hours. Infarct volume was calculated using I n response to an ischemic/hypoxic insult, extracellular concentrations of excitatory amino acids such as glutamate and aspartate are increased due to both enhanced release and impaired reuptake.
1 " Elevated levels of extracellular excitatory amino acids cause excessive neuronal stimulation of postsynaptic receptors. The /V-methyl-D-aspartate (NMDA) receptor type is one of the most extensively studied subtypes of postsynaptic ionotropic receptors. Several lines of evidence suggest that activation of the NMDA-type receptor in the acute stage of ischemia leads to substantial entry of ionic calcium into the neuron through an ion channel linked to the receptor. 5 This results in progressive irreversible neuronal damage by calcium-activated enzyme systems. 68 NMDA antagonists have been shown to effectively reduce ischemic lesions in animal stroke models, and some are currently being investigated in clinical trials. 9 Results Infarct volume of animals that received the MDL-100,453 bolus injection followed by MDL-100,453 infusion was significantly smaller than that of controls (P<.01). A significant effect of infusion on the reduction of extent of infarct size was also demonstrated (P=.015). Moreover, a statistically significant inverse correlation was demonstrated between the infarct volume and blood levels of MDL-100,453 at 60 minutes and 120 minutes after injection (r= -.33 and r= -.49, respectively).
Conclusions We demonstrated a significant neuroprotective effect of MDL-100,453 when treatment was initiated 30 minutes after ischemia began and was maintained for 24 hours. of MDL-100,453 administered 30 minutes after the start of focal ischemia and determined whether this neuroprotective effect is related to blood levels of the drug.
Materials and Methods
Nonfasted male Sprague-Dawley rats weighing 278 to 350 g were anesthetized for 3 hours with intraperitoneal chloral hydrate (400 mg/kg body weight). The left femoral artery and vein were cannulated with PE-50 polyethylene tubing for continuous monitoring of arterial blood pressure and blood sampling for analysis of blood gases and drug concentrations. Rectal temperature was monitored and kept at 37°C by a heating lamp positioned 20 cm above the animal.
We used the intraluminal suture, middle cerebral artery (MCA) occlusion model, which we described in detail previously. 12 Briefly, an intraluminal occluder, 4-0 monofilament nylon suture with its tip rounded by flame heating, was introduced through the ligated right common carotid artery (CCA) into the internal carotid artery, then gently advanced intracranially, approximately 17 mm from the CCA bifurcation. With this procedure, the suture occludes unilaterally the proximal anterior cerebral artery, distal internal carotid artery, and the MCA and origins of the posterior communicating artery.
1315
After the onset of focal cerebral ischemia, the right jugular vein was cannulated with PE-60 polyethylene tubing, and a bolus of 0.2 mL of placebo or drug solution (100 mg/kg) was injected over a 2-minute period, 30 minutes after the vascular occlusion. Then the catheter was connected to an osmotic minipump (Model 2001D, Alza Corp) that was implanted under the skin for continuous infusion of the drug over 24 hours. The pump infused 9 /iL of the drug solution or placebo per hour adjusted by body weight to deliver 4.2 mg/kg per hour of MDL-100,453. The drug concentration in plasma was determined from serial blood drawings (250 /iL at each time point, performed just before the bolus injection and at 5, 15, 30, 60, and 120 minutes and 24 hours after the bolus injection) using reverse-phase high-performance liquid chromatography to separate fiuorescently tagged amino acids (Waters AccQTas System, Millipore). Arterial samples, 300 jiL each, were drawn before and 1.5 hours after the MCA occlusion for blood gas analysis. At each blood sampling, the same amount of saline was infused. The total loss of blood was approximately 2 mL.
After completion of the 2-hour blood sampling, femoral catheters were removed, and the rats were permitted to recover from the anesthesia. Animals were then allowed free access to food and water. Twenty-four hours after the occlusion, animals were evaluated for evidence of convulsions, tremors, abnormal behavior, and other neurological abnormalities. The animals then were reanesthetized with 500 mg/kg chloral hydrate. Arterial blood at 24 hours was sampled for drug levels by cardiac puncture. The animals were decapitated, and the brains were quickly removed. We inspected the brains to confirm that the MCA orifice was completely occluded by the intraluminal suture and that no subarachnoid hemorrhage had occurred. The brains were sectioned coronally at 2-mm intervals, incubated for 30 minutes in a 2% solution of 2,3,5 -triphenyltetrazolium chloride (TTC) at 37°C, and fixed by immersion in 10% buffered formalin solution. Six brain sections per animal were stained with TTC and photographed with a 35-mm camera mounted on an operating microscope. The unstained area was defined as infarcted tissue and measured with the aid of a digitizer (Sigma-Scan v3.10, Jandel Scientific), as was the total right and left hemispheric area for each coronal section. We calculated the corrected infarct volume to compensate for the effect of brain edema. 16 ' 17 Corrected infarct volume was calculated by multiplying the corrected infarct area by slice thickness. Corrected infarct area was calculated by the following equation: corrected infarct area equals left hemisphere area minus (right hemisphere area minus infarct area). In a pilot study to determine the adequacy of the minipumps to deliver adequate blood levels of MDL-100,453, we measured the drug concentration levels in plasma during infusion of MDL-100,453 from the osmotic minipump at a rate of 100 mg/kg per 24 hours. In three nonischemic rats, the right jugular vein was cannulated and connected to an osmotic minipump containing 220 pL of MDL-100,453 solution (100 mg/kg), which was implanted under the skin. Blood samples, 250 ixL each, were serially drawn at 2, 4, 8, 20, and 24 hours after connecting the minipump.
Another three animals were used to examine the effect of MDL-100,453 on brain temperature. A small copper-constantan thermocouple, 0.003-in diameter (type IT-23, Physitemp Instruments Inc), was inserted into the right caudate putamen and fixed to the frontoparietal bone using dental cement. The body temperature was monitored with a rectal probe (T type thermocouple, OMEGA Engineering Inc) and maintained at 37°C with a heating lamp. After baseline temperature measurements, 100 mg/kg MDL-100,453 was injected intravenously as a bolus, and temperature changes in the brain were continuously monitored over 2 hours using a scanning thermocouple thermometer with 0.1°C resolution (Cole-Parmer Instrument Co). Temperatures at 15, 30, 60,90, and 120 minutes after drug injection were compared. After the experiment, the precise location of the thermocouples into the caudate putamen was confirmed by inspection of coronally cut brain slices in all animals.
For the main experiment, animals were randomly assigned before surgery to one of the following four treatment groups. The total number of animals to be studied was predetermined to be 48 (12 in each of the four treatment groups). All experiments were performed in a blinded manner. The first group received a bolus injection of saline followed by an infusion of isotonic saline for 24 hours (S-S group). The second group received a bolus injection of saline followed by an intravenous infusion of 100 mg/kg per 24 hours of MDL-100,453 (S-M group). The third group received a bolus injection of 100 mg/kg MDL-100,453 followed by an infusion of saline for 24 hours (M-S group). The fourth group received a bolus injection of 100 mg/kg MDL-100,453 followed by an infusion of 100 mg/kg per 24 hours of MDL-100,453 (M-M group). The compound displays a K, value of 109 nmol/L for its site of action, measured using MDL-100,453 is acidic due to both the phosphonate and the carboxylic acid groups present in the molecule (Fig 1) . This necessitated neutralization of the drug substance with a base to form a concentrated aqueous solution. Drug solutions were prepared by the following method. All solutions were adjusted proportionately according to body weight. For a 300-g rat, 682 fiL of 1.0N NaOH was added to 150 mg MDL-100,453. The pH was adjusted to approximately neutral (pH, 6 to 8) by adding additional 1.0N NaOH solution if necessary, and the volume was completed to 1 mL by adding saline. We used 0.2 mL of this solution for the bolus injection. This solution (220 fiL) was also used for filling the osmotic minipump reservoir, and the delivery rate was 9 fiL per hour. The osmotic minipump was incubated in 0.9% saline for at least 3 hours at 37°C before implantation.
A total of 59 rats including 11 discarded animals were used in this study. The total number of rats for the data analysis was 48. The following were reasons for exclusion: (1) subarachnoid hemorrhage (n=4), (2) the intraluminal suture did not occlude the MCA orifice at postmortem inspection (n=4), and (3) TTC vital staining was not available because of early death within 24 hours (n=3). Overdose of anesthetics was presumed to be the reason for the early death; the 3 dead animals were from the S-M, M-S, and M-M groups, respectively.
After acquiring all data, the randomization code was broken. Incorrect assignment to groups was noted for 2 rats. Therefore, the number of animals in each group was not equal. The numbers of animals in the S-S, S-M, M-S, and M-M groups were 12, 12, 11, and 13, respectively.
For parametric variables, ANOVA and post hoc analysis using the least significant difference were applied to determine the statistical significance of differences between groups. Linear regression analysis was performed to correlate the corrected infarct volume with blood level of MDL-100,453. Val- ues presented in this study are mean±SEM. A probability value less than .05 was considered significant.
Results
In the pilot studies, the drug concentration levels (micromoles per liter) at 2, 4, 8, 20, and 24 hours after connecting the osmotic minipump were 35.7±1.2, 92.2+8.0, 77.3±8.5, 71.3±4.1, and 127.3±51.6, respectively (n=3). Brain temperature was not significantly affected by the injection of MDL-100,453. At baseline, 15, 30, 60, 90, and 120 minutes after injection, the temperatures were 36.6±0.12°C, 36.5±0.03°C, 36.5±0.1°C, 36.6±0.03°C, 36.5±0.03°C, and 36.6±0.03°C, respectively (n=3).
The physiological parameters in the four groups are shown in Tables 1 and 2 . In each group, Paco 2 after MCA occlusion showed slightly lower values than baseline, and a transient elevation of mean blood pressure was noted at 30 minutes after MCA occlusion. These changes were statistically significant and thought to be responses to the brain ischemia. The differences of mean values for each blood gas parameter and mean blood pressure were not statistically significant among the four groups.
At 24 hours after MCA occlusion, no rat showed convulsions, tremors, circling behavior, or ataxia. A depressed level of consciousness was observed in some animals that had large infarcts on postmortem in all four groups.
Corrected infarct volume of the four groups was 194.4+10. 
Discussion
MDL-100,453 is a competitive NMDA antagonist that, with in vitro biochemical assays, appears very similar to other competitive NMDA antagonists. 11 However, in animal models it has several properties that make this an interesting and differentiated approach for neuroprotection. First, MDL-100,453 acts rapidly, achieving peak anticonvulsant effects as early as 2 minutes after intravenous administration. In contrast, CPPene (D(-)(£)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid) 18 and CGP 37,849 (DL-(£)-2-amino-4-methyl-5-phosphono-3-pentanoic acid), 19 also competitive NMDA antagonists being developed as neuroprotectants, exhibit a delayed pharmacologic effect after intravenous administration (at least 1 hour). This is a significant liability given our assumptions about the "window of opportunity" for such an agent to ameliorate ischemic stroke. Second, MDL-100,453 has a favorable therapeutic index with at least an eightfold separation on intravenous doses producing neurological impairment versus doses demonstrating anticonvulsant effects. Finally, MDL-100,453 has been shown to be free of cardiovascular side effects in both anesthetized and conscious dogs (P.R. Kastner, unpublished data, November 1991).
In the clinical setting, this type of neuroprotective drug will be administered after the onset of stroke. It is important that a significant neuroprotective effect of MDL-100,453 was demonstrated with postischemic administration. A statistically significant difference of the mean corrected infarct volume was demonstrated between the group receiving an initial bolus of MDL-100,453 followed by a 24-hour infusion and the group receiving placebo. Some NMDA antagonists such as MK-801 reduce brain temperature. Such a brain temperature reduction itself can reduce the extent of ischemic neuronal injury. 2024 We demonstrated that MDL-100,453 did not have direct effects on brain temperature. The significant reduction of infarct size induced by MDL-100,453 therefore cannot be attributed to effects on brain temperature.
Although the mean blood concentration levels up to 60 minutes after the initiation of the treatment were not different in the MDL-100,453 bolus and placebo infusion group when compared with the combined MDL-100,453 bolus and infusion group, a statistically significant reduction of infarct volume was not demonstrated in the former group. Infarct volume was inversely correlated with the blood level of MDL-100,453 at 60 minutes and 120 minutes after treatment initiation. Using this paradigm in nonischemic control animals, steady-state blood levels of MDL-100,453 were only observed 4 hours after infusion began in animals that did not receive an initial bolus of the drug. These results imply that the maintenance of adequate blood levels for at least several hours after stroke onset is an important factor in maintaining the neuroprotective effect of MDL-100,453 acutely after the onset of focal ischemia.
Most noncompetitive NMDA antagonists, including MK-801, are lipophilic and are able to penetrate the blood-brain barrier after systemic administration. In contrast, the blood-brain barrier penetration of competitive NMDA antagonists such as AP-7 (2-amino-7-phosphonoheptanoic acid), AP-5 (2-amino-5-phosphonoheptanoic acid), and CGS19755 (cis-4-[phosphonomethyl]-piperidine-2-carboxylic acid) is relatively poor.
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- 26 The rate of penetration of MDL-100,453 into the central nervous system through the blood-brain barrier in the acute stage of ischemia has not been determined, but our results suggest that substantial penetration occurs because of its obvious neuroprotective effects, which were correlated with plasma drug concentrations during the first few hours of therapy.
The behavioral observations suggest that MDL-100,453 is relatively well tolerated by rats, and behavioral studies in other species are proceeding. Neuronal vacuolization was observed with the noncompetitive NMDA antagonist MK-801, 27 although this vacuolization effect appears to be transient. The potential vacuolization effect of MDL-100, 453 has not yet been evaluated.
Our results suggest that MDL-100,453 can substantially reduce infarct volume in a rat stroke model that produces a large infarction. The drug is well tolerated and should be further investigated as a potential cytoprotective agent for human ischemic stroke.
